problendoПроблемы ЭндокринологииProblems of Endocrinology0375-96602308-1430Endocrinology Research Centre10.14341/probl9746problendo-9746Research ArticleОбзорыReviewsВилдаглиптин: десять лет на службе пациентам с сахарным диабетом 2-го типа. Путь открытий, инноваций и успеха в клинической практикеVildagliptin: ten years in the service for type 2 diabetes mellitus patients. The journey of discovery, innovation and success in clinical practiceДемидоваТатьяна ЮльевнаDemidovaTatiana Yu.

д.м.н., проф.

MD, PhD, Professor

t.y.demidova@gmail.com<p>ФГБОУ ВО &laquo;Российский национальный исследовательский медицинский университет им. Н.И. Пирогова&raquo;; ФГБОУ ДПО &laquo;Российская медицинская академия непрерывного профессионального образования&raquo; Минздрава России</p>Россия<p>Pirogov Russian National Research Medical University; Russian Medical Academy of Continuous Professional Education</p>Russian Federation201829122018645336347Copyright &#x00A9; Демидова Т.Ю., 20182018Демидова Т.Ю.Demidova T.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.probl-endojournals.ru/jour/article/view/9746

Сахарный диабет 2-го типа (СД2) представляет собой многофакторную полиорганную патологию. За последние 10 лет с появлением новых терапевтических возможностей, способствовавших, в частности, развитию фундаментальных исследований в области сахарного диабета, фокус терапии СД2 сменился с глюкоцентрического на целостный патофизиологический подход, основанный на управлении ключевыми патогенетическими процессами развития и прогрессирования заболевания. Ингибиторы дипептидилпептидазы-4 (иДПП-4) обладают глюкозозависимым механизмом действия, который опосредован улучшением баланса инкретиновых гормонов. Плейотропные эффекты иДПП-4 (за счет свойств инкретиновых гормонов и прямого действия препаратов) включают благоприятные сдвиги во многих метаболических процессах при СД2. иДПП-4 эффективно контролируют гликемию, безопасны и не вызывают гипогликемии и увеличения массы тела. Представлен обзор эффектов вилдаглиптина, первого из разработанных иДПП-4, при его применении в различных клинических условиях.

Type 2 diabetes mellitus is a multifactorial multiorgan disease. Over the last decade, the implementation of brand-new therapeutic opportunities led to tremendous rise of research studies in the field of diabetes as well as to shift in priorities of the management of patients with type 2 diabetes from a glucocentric approach and towards holistic control of the key underlying pathophysiological processes of the disease development and progression. The use of dipeptidyl peptidase-4 inhibitors shows good glycemic control because of physiological glucose — dependent mechanism of action mediated with the improvement of incretin hormones effects. Moreover, dipeptidyl peptidase-4 inhibitors have a wide range of pleiotropic effects owning to additional properties of incretins and inhibition of dipeptidyl peptidase enzymatic activity, which leads to beneficial impact on metabolic and pathogenetic processes of type 2 diabetes mellitus. Dipeptidyl peptidase-4 inhibitors are effective drugs with good safety profile as for risks related to type 2 diabetes and have no limitative disadvantages such as hypoglycemia and weight gain. This publication reviews vildagliptin, the first developed dipeptidyl peptidase-4 inhibitor, with an emphasis on its use in different clinical settings of diabetes management.

cахарный диабет 2-го типаингибиторы дипептидилпептидазы-4вилдаглиптингликированный гемоглобинэффективностьбезопасностьdiabetes mellitustype 2dipeptidyl peptidase-4 inhibitorsvildagliptinhaemoglobin aglycatedeffectivenesssafetyReferencesDel Prato S. Ten уears of vildagliptin. Eur Endocrinol. 2017;13(2): 54-55. doi: https://doi.org/10.17925/EE.2017.13.02.54Del Prato S. Ten уears of vildagliptin. Eur Endocrinol. 2017;13(2): 54-55. doi: https://doi.org/10.17925/EE.2017.13.02.54Ahrén B, Foley JE. The vildagliptin experience — 25 years since. The Initiation Of The Novartis Foley Je, Ahren B. The Vildagliptin Experience — 25 Years Since The Initiation Of The Novartis Glucagon-Like Peptide-1 Based Therapy Programme And 10 Years Since The First Vildagliptin Registration. Eur Endocrinol. 2017;13(2):56-61. doi: https://doi.org/10.17925/Ee.2017.13.02.56Ahrén B, Foley JE. The vildagliptin experience — 25 years since. The Initiation Of The Novartis Foley Je, Ahren B. The Vildagliptin Experience — 25 Years Since The Initiation Of The Novartis Glucagon-Like Peptide-1 Based Therapy Programme And 10 Years Since The First Vildagliptin Registration. Eur Endocrinol. 2017;13(2):56-61. doi: https://doi.org/10.17925/Ee.2017.13.02.56Виллхауэр Э. Вилдаглиптин: первый инновационный ингибитор ДПП-4. // Сахарный диабет. —2010. — Т. 13. — №3. — С. 118-120. [Wilhauer E. Vildagliptin: the first innovative DDP-4 inhibitor. Diabetes Mellitus. 2010;13(3):118-120. (In Russ.)]. doi: https://doi.org/10.14341/2072-0351-5499Виллхауэр Э. Вилдаглиптин: первый инновационный ингибитор ДПП-4. // Сахарный диабет. —2010. — Т. 13. — №3. — С. 118-120. [Wilhauer E. Vildagliptin: the first innovative DDP-4 inhibitor. Diabetes Mellitus. 2010;13(3):118-120. (In Russ.)]. doi: https://doi.org/10.14341/2072-0351-5499Strain WD, Paldanius PM. Dipeptidyl peptidase-4 inhibitor development and post-authorisation programme for vildagliptin — clinical evidence for optimised management of chronic diseases beyond type 2 diabetes. Eur Endocrinol. 2017;13(2):62-67. doi: https://doi.org/10.1795/EE.2017.13.02.62Strain WD, Paldanius PM. Dipeptidyl peptidase-4 inhibitor development and post-authorisation programme for vildagliptin — clinical evidence for optimised management of chronic diseases beyond type 2 diabetes. Eur Endocrinol. 2017;13(2):62-67. doi: https://doi.org/10.1795/EE.2017.13.02.62Kozlovski P, Paldanius PM, et al. Clinical Safety and Tolerability of Vildagliptin - Insights from Randomised Trials, Observational Studies and Post-marketing Surveillance. Eur Endocrinol. 2017;13(2):68-72. doi: https://doi.org/10.17925/EE.2017.13.02.68Kozlovski P, Paldanius PM, et al. Clinical Safety and Tolerability of Vildagliptin - Insights from Randomised Trials, Observational Studies and Post-marketing Surveillance. Eur Endocrinol. 2017;13(2):68-72. doi: https://doi.org/10.17925/EE.2017.13.02.68Nauck MA, Homberger E, Siegel EG, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab. 1986;63(2):492-498. doi: https://doi.org/10.1210/jcem-63-2-492Nauck MA, Homberger E, Siegel EG, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab. 1986;63(2):492-498. doi: https://doi.org/10.1210/jcem-63-2-492Nauck MA. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med. 2011;124(1 Suppl):S3-S18. doi: https://doi.org/10.1016/j.amjmed.2010.11.002Nauck MA. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med. 2011;124(1 Suppl):S3-S18. doi: https://doi.org/10.1016/j.amjmed.2010.11.002Ahren B, Schweizer A, Dejager S, et al. Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab. 2009;94(4):1236-1243. doi: https://doi.org/10.1210/jc.2008-2152Ahren B, Schweizer A, Dejager S, et al. Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab. 2009;94(4):1236-1243. doi: https://doi.org/10.1210/jc.2008-2152Farngren J, Persson M, Schweizer A, et al. Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes. Diabetes Obes Metab. 2014;16(9):812-818. doi: https://doi.org/10.1111/dom.12284Farngren J, Persson M, Schweizer A, et al. Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes. Diabetes Obes Metab. 2014;16(9):812-818. doi: https://doi.org/10.1111/dom.12284Michaliszyn SF, Mari A, Lee S, et al. beta-Cell function, incretin effect, and incretin hormones in obese youth along the span of glucose tolerance from normal to prediabetes to type 2 diabetes. Diabetes. 2014;63(11):3846-3855. doi: https://doi.org/10.2337/db13-1951Michaliszyn SF, Mari A, Lee S, et al. beta-Cell function, incretin effect, and incretin hormones in obese youth along the span of glucose tolerance from normal to prediabetes to type 2 diabetes. Diabetes. 2014;63(11):3846-3855. doi: https://doi.org/10.2337/db13-1951Ahren B, Foley JE. Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism. Diabetologia. 2016;59(5):907-917. doi: https://doi.org/10.1007/s00125-016-3899-2Ahren B, Foley JE. Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism. Diabetologia. 2016;59(5):907-917. doi: https://doi.org/10.1007/s00125-016-3899-2Bae EJ. Erratum to: DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control. Arch Pharm Res. 2016;39(9):1335. doi: https://doi.org/10.1007/s12272-016-0832-7Bae EJ. Erratum to: DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control. Arch Pharm Res. 2016;39(9):1335. doi: https://doi.org/10.1007/s12272-016-0832-7Chon S, Gautier JF. An Update on the Effect of Incretin-Based Therapies on beta-Cell Function and Mass. Diabetes Metab J. 2016;40(2):99-114. doi: https://doi.org/10.4093/dmj.2016.40.2.99Chon S, Gautier JF. An Update on the Effect of Incretin-Based Therapies on beta-Cell Function and Mass. Diabetes Metab J. 2016;40(2):99-114. doi: https://doi.org/10.4093/dmj.2016.40.2.99Mari A, Sallas WM, He YL, et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab. 2005;90(8):4888-4894. doi: https://doi.org/10.1210/jc.2004-2460Mari A, Sallas WM, He YL, et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab. 2005;90(8):4888-4894. doi: https://doi.org/10.1210/jc.2004-2460Mari A, Scherbaum WA, Nilsson PM, et al. Characterization of the influence of vildagliptin on model-assessed -cell function in patients with type 2 diabetes and mild hyperglycemia. J Clin Endocrinol Metab. 2008;93(1):103-109. doi: https://doi.org/10.1210/jc.2007-1639Mari A, Scherbaum WA, Nilsson PM, et al. Characterization of the influence of vildagliptin on model-assessed -cell function in patients with type 2 diabetes and mild hyperglycemia. J Clin Endocrinol Metab. 2008;93(1):103-109. doi: https://doi.org/10.1210/jc.2007-1639Rosenstock J, Foley JE, Rendell M, et al. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care. 2008;31(1):30-35. doi: https://doi.org/10.2337/dc07-1616Rosenstock J, Foley JE, Rendell M, et al. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care. 2008;31(1):30-35. doi: https://doi.org/10.2337/dc07-1616He YL, Wang Y, Bullock JM, et al. Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. J Clin Pharmacol. 2007;47(5):633-641. doi: https://doi.org/10.1177/0091270006299137He YL, Wang Y, Bullock JM, et al. Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. J Clin Pharmacol. 2007;47(5):633-641. doi: https://doi.org/10.1177/0091270006299137Drucker DJ. Enhancing Incretin Action for the Treatment of Type 2 Diabetes. Diabetes Care. 2003;26(10):2929-2940. doi: https://doi.org/10.2337/diacare.26.10.2929Drucker DJ. Enhancing Incretin Action for the Treatment of Type 2 Diabetes. Diabetes Care. 2003;26(10):2929-2940. doi: https://doi.org/10.2337/diacare.26.10.2929Kothari V, Galdo JA, Mathews ST. Hypoglycemic agents and potential anti-inflammatory activity. J Inflamm Res. 2016;9:27-38. doi: https://doi.org/10.2147/JIR.S86917Kothari V, Galdo JA, Mathews ST. Hypoglycemic agents and potential anti-inflammatory activity. J Inflamm Res. 2016;9:27-38. doi: https://doi.org/10.2147/JIR.S86917Ottobelli Chielle E, de Souza WM, da Silva TP, et al. Adipocytokines, inflammatory and oxidative stress markers of clinical relevance altered in young overweight/obese subjects. Clin Biochem. 2016;49(7-8):548-553. doi: https://doi.org/10.1016/j.clinbiochem.2016.01.003Ottobelli Chielle E, de Souza WM, da Silva TP, et al. Adipocytokines, inflammatory and oxidative stress markers of clinical relevance altered in young overweight/obese subjects. Clin Biochem. 2016;49(7-8):548-553. doi: https://doi.org/10.1016/j.clinbiochem.2016.01.003Sell H, Bluher M, Kloting N, et al. Adipose dipeptidyl peptidase-4 and obesity: correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro. Diabetes Care. 2013;36(12):4083-4090. doi: https://doi.org/10.2337/dc13-0496Sell H, Bluher M, Kloting N, et al. Adipose dipeptidyl peptidase-4 and obesity: correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro. Diabetes Care. 2013;36(12):4083-4090. doi: https://doi.org/10.2337/dc13-0496Lamers D, Famulla S, Wronkowitz N, et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes. 2011;60(7):1917-1925. doi: https://doi.org/10.2337/db10-1707Lamers D, Famulla S, Wronkowitz N, et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes. 2011;60(7):1917-1925. doi: https://doi.org/10.2337/db10-1707Zhong J, Maiseyeu A, Davis SN, Rajagopalan S. DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition. Circ Res. 2015;116(8):1491-1504. doi: https://doi.org/10.1161/CIRCRESAHA.116.305665Zhong J, Maiseyeu A, Davis SN, Rajagopalan S. DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition. Circ Res. 2015;116(8):1491-1504. doi: https://doi.org/10.1161/CIRCRESAHA.116.305665Ahmed RH, Huri HZ, Muniandy S, et al. Altered circulating concentrations of active glucagon-like peptide (GLP-1) and dipeptidyl peptidase 4 (DPP4) in obese subjects and their association with insulin resistance. Clin Biochem. 2017;50(13-14):746-749. doi: https://doi.org/10.1016/j.clinbiochem.2017.03.008Ahmed RH, Huri HZ, Muniandy S, et al. Altered circulating concentrations of active glucagon-like peptide (GLP-1) and dipeptidyl peptidase 4 (DPP4) in obese subjects and their association with insulin resistance. Clin Biochem. 2017;50(13-14):746-749. doi: https://doi.org/10.1016/j.clinbiochem.2017.03.008Barbieri M, Rizzo MR, Marfella R, et al. Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors. Atherosclerosis. 2013;227(2):349-354. doi: https://doi.org/10.1016/j.atherosclerosis.2012.12.018Barbieri M, Rizzo MR, Marfella R, et al. Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors. Atherosclerosis. 2013;227(2):349-354. doi: https://doi.org/10.1016/j.atherosclerosis.2012.12.018Hatwal A. Inflammation and incretins. Indian J Endocrinol Metab. 2012;16(Suppl 2):S239-S241. doi:https://doi.org/10.4103/2230-8210.104049 27Hatwal A. Inflammation and incretins. Indian J Endocrinol Metab. 2012;16(Suppl 2):S239-S241. doi:https://doi.org/10.4103/2230-8210.104049 27Karlsson FH, Tremaroli V, Nookaew I, et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature. 2013;498(7452):99-103. doi: https://doi.org/10.1038/nature12198Karlsson FH, Tremaroli V, Nookaew I, et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature. 2013;498(7452):99-103. doi: https://doi.org/10.1038/nature12198Tilg H, Moschen AR. Microbiota and diabetes: an evolving relationship. Gut. 2014;63(9):1513-1521. doi: https://doi.org/10.1136/gutjnl-2014-306928Tilg H, Moschen AR. Microbiota and diabetes: an evolving relationship. Gut. 2014;63(9):1513-1521. doi: https://doi.org/10.1136/gutjnl-2014-306928Grasset E, Puel A, Charpentier J, et al. A Specific Gut Microbiota Dysbiosis of Type 2 Diabetic Mice Induces GLP-1 Resistance through an Enteric NO-Dependent and Gut-Brain Axis Mechanism. Cell Metab. 2017;25(5):1075-1090 e1075. doi: https://doi.org/10.1016/j.cmet.2017.04.013Grasset E, Puel A, Charpentier J, et al. A Specific Gut Microbiota Dysbiosis of Type 2 Diabetic Mice Induces GLP-1 Resistance through an Enteric NO-Dependent and Gut-Brain Axis Mechanism. Cell Metab. 2017;25(5):1075-1090 e1075. doi: https://doi.org/10.1016/j.cmet.2017.04.013Forslund K, Hildebrand F, Nielsen T, et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature. 2015;528(7581):262-266. doi: https://doi.org/10.1038/nature15766Forslund K, Hildebrand F, Nielsen T, et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature. 2015;528(7581):262-266. doi: https://doi.org/10.1038/nature15766Lv Y, Zhao X, Guo W, et al. The Relationship between Frequently Used Glucose-Lowering Agents and Gut Microbiota in Type 2 Diabetes Mellitus. J Diabetes Res. 2018;2018:1890978. doi: https://doi.org/10.1155/2018/1890978Lv Y, Zhao X, Guo W, et al. The Relationship between Frequently Used Glucose-Lowering Agents and Gut Microbiota in Type 2 Diabetes Mellitus. J Diabetes Res. 2018;2018:1890978. doi: https://doi.org/10.1155/2018/1890978Zhang Q, Xiao X, Li M, et al. Vildagliptin increases butyrate-producing bacteria in the gut of diabetic rats. PLoS One. 2017;12(10):e0184735. doi: https://doi.org/10.1371/journal.pone.0184735Zhang Q, Xiao X, Li M, et al. Vildagliptin increases butyrate-producing bacteria in the gut of diabetic rats. PLoS One. 2017;12(10):e0184735. doi: https://doi.org/10.1371/journal.pone.0184735Olivares M, Neyrinck AM, Potgens SA, et al. The DPP-4 inhibitor vildagliptin impacts the gut microbiota and prevents disruption of intestinal homeostasis induced by a Western diet in mice. Diabetologia. 2018;61(8):1838-1848. doi: https://doi.org/10.1007/s00125-018-4647-6Olivares M, Neyrinck AM, Potgens SA, et al. The DPP-4 inhibitor vildagliptin impacts the gut microbiota and prevents disruption of intestinal homeostasis induced by a Western diet in mice. Diabetologia. 2018;61(8):1838-1848. doi: https://doi.org/10.1007/s00125-018-4647-6Finan B, Muller TD, Clemmensen C, et al. Reappraisal of GIP Pharmacology for Metabolic Diseases. Trends Mol Med. 2016;22(5):359-376. doi: https://doi.org/10.1016/j.molmed.2016.03.005Finan B, Muller TD, Clemmensen C, et al. Reappraisal of GIP Pharmacology for Metabolic Diseases. Trends Mol Med. 2016;22(5):359-376. doi: https://doi.org/10.1016/j.molmed.2016.03.005Schweizer A, Couturier A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naive patients with Type 2 diabetes. Diabet Med. 2007;24(9):955-961. doi: https://doi.org/10.1111/j.1464-5491.2007.02191.xSchweizer A, Couturier A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naive patients with Type 2 diabetes. Diabet Med. 2007;24(9):955-961. doi: https://doi.org/10.1111/j.1464-5491.2007.02191.xGoke B, Hershon K, Kerr D, et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naive patients with type 2 diabetes: comparison with metformin. Horm Metab Res. 2008;40(12):892-895. doi: https://doi.org/10.1055/s-0028-1082334Goke B, Hershon K, Kerr D, et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naive patients with type 2 diabetes: comparison with metformin. Horm Metab Res. 2008;40(12):892-895. doi: https://doi.org/10.1055/s-0028-1082334Evans M, Schweizer A, Foley JE. An approach to reporting pooled HbA1c reductions to maximize the accuracy of between — drug comparisons: HbA1c reductions with vildagliptin monotherapy. Diabetes. 2015;(64):suppl. 1:A332.Evans M, Schweizer A, Foley JE. An approach to reporting pooled HbA1c reductions to maximize the accuracy of between — drug comparisons: HbA1c reductions with vildagliptin monotherapy. Diabetes. 2015;(64):suppl. 1:A332.Bosi E, Dotta F, Jia Y, Goodman M. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2009;11(5):506-515. doi: https://doi.org/10.1111/j.1463-1326.2009.01040.xBosi E, Dotta F, Jia Y, Goodman M. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2009;11(5):506-515. doi: https://doi.org/10.1111/j.1463-1326.2009.01040.xBosi E, Camisasca RP, Collober C, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care. 2007;30(4):890-895. doi: https://doi.org/10.2337/dc06-1732Bosi E, Camisasca RP, Collober C, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care. 2007;30(4):890-895. doi: https://doi.org/10.2337/dc06-1732Matthews DR, Dejager S, Ahren B, et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab. 2010;12(9):780-789. doi: https://doi.org/10.1111/j.1463-1326.2010.01233.xMatthews DR, Dejager S, Ahren B, et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab. 2010;12(9):780-789. doi: https://doi.org/10.1111/j.1463-1326.2010.01233.xFerrannini E, Fonseca V, Zinman B, et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab. 2009;11(2):157-166. doi: https://doi.org/10.1111/j.1463-1326.2008.00994.xFerrannini E, Fonseca V, Zinman B, et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab. 2009;11(2):157-166. doi: https://doi.org/10.1111/j.1463-1326.2008.00994.xLukashevich V, Del Prato S, Araga M, Kothny W. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea. Diabetes Obes Metab. 2014;16(5):403-409. doi: https://doi.org/10.1111/dom.12229Lukashevich V, Del Prato S, Araga M, Kothny W. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea. Diabetes Obes Metab. 2014;16(5):403-409. doi: https://doi.org/10.1111/dom.12229Fonseca V, Schweizer A, Albrecht D, et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia. 2007;50(6):1148-1155. doi: https://doi.org/10.1007/s00125-007-0633-0Fonseca V, Schweizer A, Albrecht D, et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia. 2007;50(6):1148-1155. doi: https://doi.org/10.1007/s00125-007-0633-0Ved P, Shah S. Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over 3 months in patients with type 2 diabetes mellitus. Indian J Endocrinol Metab. 2012;16 Suppl 1:S110-S113. doi: https://doi.org/10.4103/2230-8210.94258Ved P, Shah S. Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over 3 months in patients with type 2 diabetes mellitus. Indian J Endocrinol Metab. 2012;16 Suppl 1:S110-S113. doi: https://doi.org/10.4103/2230-8210.94258Aroda VR, Henry RR, Han J, et al. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: metaanalysis and systematic review. Clin Ther. 2012;34(6):1247-1258:e1222. doi: https://doi.org/10.1016/j.clinthera.2012.04.013Aroda VR, Henry RR, Han J, et al. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: metaanalysis and systematic review. Clin Ther. 2012;34(6):1247-1258:e1222. doi: https://doi.org/10.1016/j.clinthera.2012.04.013Esposito K, Chiodini P, Maiorino MI, et al. A nomogram to estimate the HbA1c response to different DPP-4 inhibitors in type 2 diabetes: a systematic review and metaanalysis of 98 trials with 24 163 patients. BMJ Open. 2015;5(2):e005892. doi: https://doi.org/10.1136/bmjopen-2014-005892Esposito K, Chiodini P, Maiorino MI, et al. A nomogram to estimate the HbA1c response to different DPP-4 inhibitors in type 2 diabetes: a systematic review and metaanalysis of 98 trials with 24 163 patients. BMJ Open. 2015;5(2):e005892. doi: https://doi.org/10.1136/bmjopen-2014-005892Monnier L, Lapinski H, Colette C. Contributions of Fasting and Postprandial Plasma Glucose Increments to the Overall Diurnal Hyperglycemia of Type 2 Diabetic Patients: Variations with increasing levels of HbA1c. Diabetes Care. 2003;26(3):881-885. doi: https://doi.org/10.2337/diacare.26.3.881Monnier L, Lapinski H, Colette C. Contributions of Fasting and Postprandial Plasma Glucose Increments to the Overall Diurnal Hyperglycemia of Type 2 Diabetic Patients: Variations with increasing levels of HbA1c. Diabetes Care. 2003;26(3):881-885. doi: https://doi.org/10.2337/diacare.26.3.881Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006;295(14):1681-1687. doi: https://doi.org/10.1001/jama.295.14.1681Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006;295(14):1681-1687. doi: https://doi.org/10.1001/jama.295.14.1681Marso SP, McGuire DK, Zinman B, et al. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. N Engl J Med. 2017;377(8):723-732. doi: https://doi.org/10.1056/NEJMoa1615692Marso SP, McGuire DK, Zinman B, et al. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. N Engl J Med. 2017;377(8):723-732. doi: https://doi.org/10.1056/NEJMoa1615692Rizzo MR, Barbieri M, Marfella R, Paolisso G. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care. 2012;35(10):2076-2082. doi: https://doi.org/10.2337/dc12-0199Rizzo MR, Barbieri M, Marfella R, Paolisso G. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care. 2012;35(10):2076-2082. doi: https://doi.org/10.2337/dc12-0199Xiaoyan C, Jing W, Xiaochun H, et al. Effects of vildagliptin versus saxagliptin on daily acute glucose fluctuations in Chinese patients with T2DM inadequately controlled with a combination of metformin and sulfonylurea. Curr Med Res Opin. 2016;32(6):1131-1136. doi: https://doi.org/10.1185/03007995.2016.1162773Xiaoyan C, Jing W, Xiaochun H, et al. Effects of vildagliptin versus saxagliptin on daily acute glucose fluctuations in Chinese patients with T2DM inadequately controlled with a combination of metformin and sulfonylurea. Curr Med Res Opin. 2016;32(6):1131-1136. doi: https://doi.org/10.1185/03007995.2016.1162773Clinicaltrials.gov [Internet]. VERIFY: A study to compare combination regimen with vildagliptin & metformin versus metformin in treatment-naive patients with type 2 diabetes mellitus [cited 2018 Apr 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT01528254?term= vildagliptin+VERIFY&rank=1Clinicaltrials.gov [Internet]. VERIFY: A study to compare combination regimen with vildagliptin & metformin versus metformin in treatment-naive patients with type 2 diabetes mellitus [cited 2018 Apr 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT01528254?term= vildagliptin+VERIFY&rank=1Ahren B, Mathieu C, Bader G, et al. Efficacy of vildagliptin versus sulfonylureas as add-on therapy to metformin: comparison of results from randomised controlled and observational studies. Diabetologia. 2014;57(7):1304-1307. doi: https://doi.org/10.1007/s00125-014-3222-zAhren B, Mathieu C, Bader G, et al. Efficacy of vildagliptin versus sulfonylureas as add-on therapy to metformin: comparison of results from randomised controlled and observational studies. Diabetologia. 2014;57(7):1304-1307. doi: https://doi.org/10.1007/s00125-014-3222-zSchweizer A, Dejager S. Experience with vildagliptin in patients >/=75 years with type 2 diabetes and moderate or severe renal impairment. Diabetes Ther. 2013;4(2):257-267. doi: https://doi.org/10.1007/s13300-013-0027-xSchweizer A, Dejager S. Experience with vildagliptin in patients >/=75 years with type 2 diabetes and moderate or severe renal impairment. Diabetes Ther. 2013;4(2):257-267. doi: https://doi.org/10.1007/s13300-013-0027-xMcMurray JJV, Ponikowski P, Bolli GB, et al. Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure: A Randomized Placebo-Controlled Trial. JACC Heart Fail. 2018;6(1):8-17. doi: https://doi.org/10.1016/j.jchf.2017.08.004McMurray JJV, Ponikowski P, Bolli GB, et al. Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure: A Randomized Placebo-Controlled Trial. JACC Heart Fail. 2018;6(1):8-17. doi: https://doi.org/10.1016/j.jchf.2017.08.004Guo WQ, Li L, Su Q, et al. Effect of Dipeptidyl Peptidase-4 Inhibitors on Heart Failure: A Network Metaanalysis. Value Health. 2017;20(10):1427-1430. doi: https://doi.org/10.1016/j.jval.2017.04.010Guo WQ, Li L, Su Q, et al. Effect of Dipeptidyl Peptidase-4 Inhibitors on Heart Failure: A Network Metaanalysis. Value Health. 2017;20(10):1427-1430. doi: https://doi.org/10.1016/j.jval.2017.04.010McInnes G, Evans M, Del Prato S, et al. Cardiovascular and heart failure safety profile of vildagliptin: a metaanalysis of 17 000 patients. Diabetes Obes Metab. 2015;17(11):1085-1092. doi: https://doi.org/10.1111/dom.12548McInnes G, Evans M, Del Prato S, et al. Cardiovascular and heart failure safety profile of vildagliptin: a metaanalysis of 17 000 patients. Diabetes Obes Metab. 2015;17(11):1085-1092. doi: https://doi.org/10.1111/dom.12548Macauley M, Hollingsworth KG, Smith FE, et al. Effect of vildagli ptin on hepatic steatosis. J Clin Endocrinol Metab. 2015;100(4):1578-1585. doi: https://doi.org/10.1210/jc.2014-3794Macauley M, Hollingsworth KG, Smith FE, et al. Effect of vildagli ptin on hepatic steatosis. J Clin Endocrinol Metab. 2015;100(4):1578-1585. doi: https://doi.org/10.1210/jc.2014-3794Mathieu C, Barnett AH, Brath H, et al. Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE). Int J Clin Pract. 2013;67(10):947-956. doi: https://doi.org/10.1111/ijcp.12252Mathieu C, Barnett AH, Brath H, et al. Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE). Int J Clin Pract. 2013;67(10):947-956. doi: https://doi.org/10.1111/ijcp.12252Rosales R, Abou Jaoude E, Al-Arouj M, et al. Clinical effectiveness and safety of vildagliptin in >19 000 patients with type 2 diabetes: the GUARD study. Diabetes Obes Metab. 2015;17(6):603-607. doi: https://doi.org/10.1111/dom.12436Rosales R, Abou Jaoude E, Al-Arouj M, et al. Clinical effectiveness and safety of vildagliptin in >19 000 patients with type 2 diabetes: the GUARD study. Diabetes Obes Metab. 2015;17(6):603-607. doi: https://doi.org/10.1111/dom.12436Bluher M, Kurz I, Dannenmaier S, Dworak M. Efficacy and safety of vildagliptin in clinical practice-results of the PROVIL-study. World J Diabetes. 2012;3(9):161-169. doi: https://doi.org/10.4239/wjd.v3.i9.161Bluher M, Kurz I, Dannenmaier S, Dworak M. Efficacy and safety of vildagliptin in clinical practice-results of the PROVIL-study. World J Diabetes. 2012;3(9):161-169. doi: https://doi.org/10.4239/wjd.v3.i9.161Kolaczynski WM, Hankins M, Ong SH, et al. Microvascular Outcomes in Patients with Type 2 Diabetes Treated with Vildagliptin vs. Sulfonylurea: A Retrospective Study Using German Electronic Medical Records. Diabetes Ther. 2016;7(3):483-496. doi: https://doi.org/10.1007/s13300-016-0177-8Kolaczynski WM, Hankins M, Ong SH, et al. Microvascular Outcomes in Patients with Type 2 Diabetes Treated with Vildagliptin vs. Sulfonylurea: A Retrospective Study Using German Electronic Medical Records. Diabetes Ther. 2016;7(3):483-496. doi: https://doi.org/10.1007/s13300-016-0177-8Eriksson JW, Bodegard J, Nathanson D, et al. Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality. Diabetes Res Clin Pract. 2016;117:39-47. doi: https://doi.org/10.1016/j.diabres.2016.04.055Eriksson JW, Bodegard J, Nathanson D, et al. Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality. Diabetes Res Clin Pract. 2016;117:39-47. doi: https://doi.org/10.1016/j.diabres.2016.04.055Williams R, de Vries F, Kothny W, et al. Cardiovascular safety of vildagliptin in patients with type 2 diabetes: A European multi-database, non-interventional post-authorization safety study. Diabetes Obes Metab. 2017;19(10):1473-1478. doi: https://doi.org/10.1111/dom.12951Williams R, de Vries F, Kothny W, et al. Cardiovascular safety of vildagliptin in patients with type 2 diabetes: A European multi-database, non-interventional post-authorization safety study. Diabetes Obes Metab. 2017;19(10):1473-1478. doi: https://doi.org/10.1111/dom.12951

The authors declare that there are no conflicts of interest present.